In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $36.00. The company’s shares closed yesterday at $10.61.
According to TipRanks, Canino is an analyst with an average return of -23.7% and a 29.47% success rate. Canino covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Nuvalent, and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zentalis Pharmaceuticals with a $32.89 average price target, representing a 209.99% upside. In a report released on November 28, UBS also maintained a Buy rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
ZNTL market cap is currently $738.1M and has a P/E ratio of -2.25.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZNTL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zentalis Pharmaceuticals (ZNTL) Company Description:
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company’s product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
Read More on ZNTL:
- Zentalis downgraded to Neutral at Wedbush as strategy shifts for azeno
- Zentalis downgraded to Neutral from Outperform at Wedbush
- Zentalis price target lowered to $29 from $50 at Wells Fargo
- Zentalis price target lowered to $46 from $55 at H.C. Wainwright
- Zentalis selloff ‘misses the bigger picture,’ says Oppenheimer
